University of Kentucky

UKnowledge
Microbiology, Immunology, and Molecular
Genetics Faculty Publications

Microbiology, Immunology, and Molecular
Genetics

5-1993

Reversal of Age-Associated Decline in Immune Response to PnuImune Vaccine by Supplementation with the Steroid Hormone
Dehydroepiandrosterone
Manju Garg
University of Kentucky

Subbarao Bondada
University of Kentucky, bondada@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub
Part of the Immunology and Infectious Disease Commons, Medical Immunology Commons, Medical
Microbiology Commons, and the Molecular Genetics Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Garg, Manju and Bondada, Subbarao, "Reversal of Age-Associated Decline in Immune Response to PnuImune Vaccine by Supplementation with the Steroid Hormone Dehydroepiandrosterone" (1993).
Microbiology, Immunology, and Molecular Genetics Faculty Publications. 116.
https://uknowledge.uky.edu/microbio_facpub/116

This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at
UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.

Reversal of Age-Associated Decline in Immune Response to Pnu-Imune Vaccine
by Supplementation with the Steroid Hormone Dehydroepiandrosterone
Notes/Citation Information
Published in Infection and Immunity, v. 61, no. 5, p. 2238-2241.
Copyright © 1993, American Society for Microbiology
The copyright holder has granted the permission for posting the article here.

This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/116

Vol. 61, No. 5

INFECTION AND IMMUNITY, May 1993, p. 2238-2241
0019-9567/93/052238-04$02.00/0
Copyright C 1993, American Society for Microbiology

Reversal of Age-Associated Decline in Immune Response to
Pnu-Imune Vaccine by Supplementation with the Steroid
Hormone Dehydroepiandrosterone
MANJU GARG AND SUBBARAO BONDADA*
Department of Microbiology and Immunology, Sanders-Brown Center on Aging,
University of Kentucky, Lexington, Kentucky 40536-0230
Received 14 December 1992/Accepted 22 February 1993

Pneumococcal infections remain an important cause of
morbidity and mortality in the United States, particularly in
children less than 2 years of age, in elderly persons, and in
patients with AIDS (2, 10, 11). To prevent these infections,
a vaccine made up of capsular polysaccharides from 23
commonly occurring pneumococcal bacteria was developed
and was shown to reduce significantly the occurrence of
pneumonia in a young healthy population (12). However, the
vaccine was not protective in infants and was only moderately effective in the aged population (12, 19) and therefore
needs to be improved. The recently described increase in the
incidence of antibiotic-resistant strains of pneumococcal
bacteria further emphasizes the need to make the current
vaccine more efficacious (16). We developed a model system
to study the immune responses of mice to pneumococcal
polysaccharide (PS) antigens present in the commercial
vaccines and showed that the splenic antibody responses to
the 23-valent Pnu-Imune vaccine declined with increasing
age (6).
In vivo, the immune microenvironment is a system composed of many components derived from the immune, nervous, and endocrine systems. Although immune responses
can be elicited from isolated lymphocyte populations, there
is growing evidence to suggest that factors of neural and
endocrine origins can influence immune cell function (18).
Recently, a newer concept was proposed to explain immunosenescence; i.e., the age-associated decline in immune
function is due not only to loss of immune cell function (7,
13, 17, 20, 22) but also to altered endocrine status during
aging (3). Thus, changing the milieu of steroid hormones
such as glucocorticoids, dehydroepiandrosterone (DHEA),
testosterone, and dihydroxytestosterone was shown to
change the pattern and quantity of lymphokine production
by T cells and thus affect immune responses in vivo (1, 4, 5).
DHEA and its precursor, DHEA-sulfate (DHEA-S), are
made by adrenal glands, and their levels decrease with
increasing age in both males and females (15). Daynes and
Araneo showed that an exogenous supply of DHEA-S to
aged animals reversed the age-associated abnormal secretion
of lymphokines from T cells (decrease in interleukin-2 [IL-2]
*

and increase in IL-4, IL-5, and gamma interferon) and
especially enhanced the IL-2 production and the antibody
responses to protein antigens (3).
Since the in vitro immune response to several type 2
thymus-independent (TI) antigens and to the vaccine is
enhanced by T-cell-derived lymphokines (5a, 8, 9) and since
DHEA was shown to restore T-cell function in the aged mice
(1, 3), we studied the effect of DHEA-S therapy on the
immune responses of aged mice to the pneumococcal vaccine. Short-term treatment with DHEA or DHEA-S significantly enhanced the antibody-forming cell responses of old
but not young mice to the Pnu-Imune vaccine.
Female CB-17 mice were bred and housed in our animal
colony. Female BALB/c-CRL mice were obtained from the
National Institute of Aging (Bethesda, Md.). Young mice
were 4 to 5 months old. Aged mice were 22 to 24 months old
in the case of BALB/c mice, while the CB-17 mice were 15
to 17 months old. The 23-valent Pnu-Imune 23 vaccine was
obtained from Lederle Laboratories (Pearl River, N.Y.).
DHEA and DHEA-S (Sigma Chemical Co., St. Louis, Mo.)
were dissolved in 95% ethanol and in propylene glycol,
respectively. Initially, DHEA-S was used since it is not as
rapidly degraded as DHEA (3, 15). The sulfate form of the
hormone is taken up by the macrophages and converted into
hormone and is released into the local environment and
circulation, because of which higher local concentrations of
hormone are obtained with DHEA-S than with DHEA in
lymphoid tissues (4, 5).
Lymphoid cells were obtained from spleen, mesenteric
lymph nodes (MLN), and draining peripheral brachial and
axillary lymph nodes (PLN) and were processed as described previously (6, 9). The numbers of immunoglobulin
M-producing plaque-forming cells (PFC) specific for PS were
detected in individual mice with sheep erythrocytes (SRBC)
coated with Pnu-Imune vaccine as described earlier (6).
Previously, we showed that 11.5 ,ug is the optimal vaccine
dose for both young and old mice, that the responses peaked
on day 5, and that this method detected antibody responses
to 21 of 23 component polysaccharides in the vaccine (6).
Our previous studies found that 80 to 90% of the PFC
response was specific to the capsular polysaccharides
whereas 10 to 20% of the response was directed against the
cell wall polysaccharide, which is a common contaminant in

Corresponding author.
2238

Downloaded from http://iai.asm.org/ on February 20, 2019 by guest

Recently, we reported that murine antibody responses to the 23-valent pneumococcal polysaccharide
(Pnu-Imune) vaccine declined with age. Here we present data to support the concept that age-associated
immune defects are not only due to intrinsic defects in immune cells but are also due to extrinsic factors
emanating from the neuroendocrine system. We found that supplementation with dehydroepiandrosterone, a
steroid hormone known to be reduced in the aged, corrects the immune deficiency of aged mice and significantly
enhanced their splenic immune responses to the Pnu-Imune vaccine.

VOL. 61, 1993

NOTES

2239

600

A. 3 h treatment

500

a-.
4

500

0)

u

400

c.)

.)

co

400
300

o
'

300

0. - -

200

4

vo

100

.~ 0

200

I.
.

0

600

100
DO2
A h,
--+
n 4--+
D. 44
LIedLreatenL

T

5~400-

0

C~300
Days Post immunization
FIG. 1. Young (4 to 5 months) and old (15 to 17 months) CB-17
mice were injected s.c. with 100 xLg of DHEA-S or vehicle alone,
and 3 h later they were immunized at the same site with 11.5 ±Lg of
Pnu-Imune vaccine, a dose shown to be optimal for both young and
aged mice in our previous studies (6). On days 3, 5, and 7, the
Pnu-Imune-specific PFC were assayed by using vaccine-coupled
SRBC and uncoupled SRBC as described in the text. The data
represent mean responses of three to five mice, and the bars
represent SE values. Representative results from one of three
experiments are presented.

capsular polysaccharides (6). The number of PFC on uncoupled SRBC was evaluated routinely (10 to 20 PFC per 106
cells) and was subtracted from all experimental values. Each
control and experimental group consisted of three to five
mice, and the values reported represent the arithmetic mean
+ standard error (SE). The differences between control and
DHEA-treated groups were evaluated by Student's t test. P
values of less than 0.05 were considered significant.
To enhance the antibody responses of aged mice to the
Pnu-Imune vaccine, 100 ,ug of DHEA-S per mouse or the
vehicle was injected subcutaneously (s.c.) near the shoulder
area of young as well as aged CB-17 mice. Three hours later,
an optimal dose of Pnu-Imune vaccine was injected s.c. at
the same skin site. As shown clearly in Fig. 1, a local
injection of DHEA-S prior to immunization with the vaccine
enhanced the splenic responses of aged mice to the PnuImune vaccine on all days assayed but the peak response
was on day 5. In young mice, DHEA-S therapy has only a
moderate influence on the antibody responses to the vaccine. The hormone treatment did not increase the size of the
spleen, and the results were similar if expressed as PFC per
spleen. As reported previously, the draining PLN did not
respond to the vaccine (6), and the hormone treatment had
modestly increased their response (0 PFC in control versus
25 PFC per 106 cells in DHEA-injected mice). To determine
whether DHEA-S will be effective at later time points, aged
mice were given DHEA-S as described above and then were
challenged s.c. with the Pnu-Imune vaccine 3 or 24 h later.
Both 3 (Fig. 2A) and 24 (Fig. 2B) h of DHEA-S therapy were
equally effective in significantly enhancing the Pnu-Imunespecific responses from aged mice compared with those from
control mice that were not treated with the hormone.
Since DHEA-S requires the action of a sulfatase to generate physiologically active DHEA, a step that could differ in
young and old mice, we tested the effect of DHEA itself on
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FIG. 2. DHEA-S was administered to old (22 to 24 months)
BALB/c mice as described in the legend to Fig. 1, but the vaccine
was injected 3.0 (A) or 24 (B) h later at the same site. Five days later,
levels of Pnu-Imune-specific PFC were determined. Results represent mean responses of three to five mice per group, and the bars
represent SE values. Similar results were obtained in another
experiment.

the vaccine response. Young and old BALB/c mice were
given DHEA hormone near the shoulder region, and 3 h later
an optimal dose of the vaccine was given s.c. Antibody
responses from the spleen and draining PLN were assayed
on day 5, and the results shown in Fig. 3 demonstrated that
direct administration of DHEA also augmented the splenic
PFC responses from old mice to Pnu-Imune vaccine. Once
again, the hormone had only a very modest effect on the
vaccine responses of young mice, suggesting that the lack of
effect with DHEA-S in the young was not due to a difference
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FIG. 3. The hormone DHEA (10 p.g) in 95% ethanol or the
vehicle alone was injected s.c. into young (4 to 5 months) or old (22
to 24 months) BALB/c mice, and 3 h later mice were immunized
with 11.5 p,g of Pnu-Imune vaccine. The vaccine-specific PFC were
measured on day 5, when the Pnu-Imune response was previously
found to be maximum (Fig. 1) (6). Results represent mean responses
of three to five mice per group. Bars represent SE values.
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suggest a means by which the pneumococcal vaccine can be
made more effective for such populations.
Our thanks are due to Thomas Roszman and Joe McGillis for a
critical review of the manuscript and to David Lavrin for suggesting
to us the possibility of DHEA-S therapy.
This work is supported in part by the NIH grants AI21490,
AG05731, and K04AG00422 and by a grant from the Tobacco and
Health Research Institute at the University of Kentucky.
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into young

(4

to

5 months) or old (22 to 24 months) BALB/c mice. Pnu-Imune
vaccine was injected i.p. 24 h later into these mice, and the
vaccine-specific PFC were measured on day 5. Mean responses of
four to six mice are represented, and the bars denote the SE values.

in the DHEA-sulfatase activity. There was no PFC response
in the PLN in the mice given vaccine only, whereas mice
treated with DHEA and vaccine gave a mild response (18 to
20 PFC per 106 cells).
Our previous studies showed that PFC responses to the
vaccine from the mucosally associated lymph nodes were
not decreased as a function of age and that intraperitoneal
(i.p.) but not s.c. challenge is necessary to obtain vaccine
PFC response from the MLN (6). To determine the effect of
DHEA-S treatment on MLN responses, and to see whether
systemic administration has the same effect as local injection, DHEA-S was administered i.p. into old mice which
were immunized 24 h later with the vaccine via the same
route. This systemic DHEA-S therapy also enhanced the
splenic PFC responses from old mice (Fig. 4). As reported
earlier, in old mice MLN response to the vaccine was well
preserved (6) but it was not enhanced (data not shown). This
is in agreement with previous reports that the DHEAsulfatase activity is higher in spleen than in mucosal tissues
such as MLN and Peyer's patches (4).
Since PSs belong to the TI class of antigens, it is unclear
as to how DHEA-S therapy was effective in boosting the
immune responses of old mice to these antigens. The antibody responses to such type 2 TI antigens as PS are known
to require T-cell-derived lymphokines but not an antigenspecific T-helper cell (14). Our laboratory showed that B-cell
responses to trinitrophenylated Ficoll, another prototypic
type 2 TI antigen, are dependent on supplementation with
IL-5 or splenic accessory cells (8, 9), and our unpublished
observations suggest that in vitro responses to the PnuImune vaccine also have similar requirements. Therefore,
regulation of IL-5 production may not be the primary mechanism since DHEA therapy increases IL-2 secretion while
decreasing IL-5 secretion (1, 3, 5). Instead, the immunoenhancing effect of DHEA may depend on its ability to directly
affect B-cell function or indirectly enhance IL-1 production
by the accessory cells. Another explanation relates to the
ability of DHEA to down regulate the age-associated increase in the production of gamma interferon (1), since we
and others find that gamma interferon inhibits PS responses
in vitro (unpublished observations) and in vivo (21).
Since the efficacy of the Pnu-Imune vaccine in older
individuals and in splenectomized patients has not been as
high as in young adults, our results with DHEA therapy
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